DataString Consulting Company Logo
DataString Consulting Company Logo
Opicapone Market
Home»Recent Reports»Opicapone Market

Opicapone Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802169, Published - April 2025

Segmented in Drug Formulation (Capsule, Tablet), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Therapeutic Application, Patient Demographics and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Opicapone Market Outlook

The market, for Opicapone was estimated at $714.2 million in 2024; and it is anticipated to increase to $1.0 billion by 2030 with projections indicating a growth to around $1.4 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 6.0% over the forecast period. The increasing popularity and growing demand for Opicapone in the market indicate its emerging importance and rising appeal among consumers worldwide. Factors contributing significantly to this trend include the expanding population of individuals with Parkinsons disease well as a deeper understanding of neurodegenerative disorders and the development of individualized treatment approaches. Moreover the integration of Opicapone into these personalized treatment strategies highlights its significance in addressing motor fluctuations that pose a significant challenge for individuals, with Parkinsons disease.


Opicapone has been revolutionary as a generation catechol O methyltransferase (COMTE) inhibitor in the treatment of Parkinsons disease alongside Levodopa therapy. Its introduction as a daily oral capsule has significantly improved patient adherence and administration compared to earlier COMTE inhibitors, with more frequent dosages.


Market Size Forecast & Key Insights

2019
$714M2024
2029
$1.3B2034

Absolute Growth Opportunity = $565M

The Opicapone market is projected to grow from $714.2 million in 2024 to $1.28 billion in 2034. This represents a CAGR of 6.0%, reflecting rising demand across Parkinson's Disease Treatment, Neurodegenerative Disease Management and Drug Combination Therapy.

The Opicapone market is set to add $565 million between 2024 and 2034, with manufacturer targeting Retail Pharmacies & Online Pharmacies Distribution Channel projected to gain a larger market share.

With Rising prevalence of parkinsons disease, and Advancements in drug delivery methods, Opicapone market to expand 79% between 2024 and 2034.

Opportunities in the Opicapone Market

Collaborating with Tech Innovations

Embracing technology could open up opportunities for Opicapone in the pharmaceutical industry by working together with advanced medical technologies, like drug delivery systems to boost patient compliance and results – ultimately strengthening Opicapones competitive edge in a crowded market.

Tapping into Asian Markets and Meeting Evolving Consumer Needs

The worldwide expansion of Parkinsons disease presents an opportunity for Opicapone in the Asian market as countries such as China and India have a growing elderly population susceptible to neurological conditions like Parkinsons disease and therefore increasing the need for treatments, like Opicapone.

today's consumers are increasingly focused on their health and well being. Are choosing to take proactive steps to maintain good health rather than relying on reactive treatment approaches. In line with this shift in consumer behavior conducti a study to better understand how Opicapone works and its benefits could lead to an increase, in market presence and create various growth possibilities.

Growth Opportunities in North America and Europe

Europe Outlook

In Europe's healthcare industry is seeing a growing demand for Opicapone due to the increasing cases of Parkinsons disease and the push for treatments that stand out as innovative solutions for patients in need of care and treatment options available to them today. The market competition involves pharmaceutical companies who have a strong presence in the field but also sees a positive acceptance of new treatment options among the well informed public who are open to exploring new medical advancements for their conditions. With stringent regulations guiding the healthcare landscape in Europe and emphasizing safety and effectiveness standards rigorously upheld across the board; Opicapone emerges as an addition to traditional Levodopa therapy, in addressing Parkinsons disease effectively.

North America Outlook

Being a participant in the worldwide medical field industry and due to its advanced healthcare system and innovative approaches to treating Parkinsons disease; North America offers notable opportunities for Opicapone drug adoption in the market despite the fierce competition among leading pharmaceutical companies striving for market dominance in the region. Opicapones unique formula tailored to suppress COMT enzyme stands out as an advantage, in addressing motor fluctuations experienced by Parkinsons patients within this competitive landscape. Rising awareness of the disease and its complexities in North America is fueling the demand for Opicapone due to factors such as increasing healthcare spending and research efforts well as a growing elderly population prone, to neuromuscular conditions.

North America Outlook

Being a participant in the worldwide medical field industry and due to its advanced healthcare system and innovative approaches to treating Parkinsons disease; North America offers notable opportunities for Opicapone drug adoption in the market despite the fierce competition among leading pharmaceutical companies striving for market dominance in the region. Opicapones unique formula tailored to suppress COMT enzyme stands out as an advantage, in addressing motor fluctuations experienced by Parkinsons patients within this competitive landscape. Rising awareness of the disease and its complexities in North America is fueling the demand for Opicapone due to factors such as increasing healthcare spending and research efforts well as a growing elderly population prone, to neuromuscular conditions.

Europe Outlook

In Europe's healthcare industry is seeing a growing demand for Opicapone due to the increasing cases of Parkinsons disease and the push for treatments that stand out as innovative solutions for patients in need of care and treatment options available to them today. The market competition involves pharmaceutical companies who have a strong presence in the field but also sees a positive acceptance of new treatment options among the well informed public who are open to exploring new medical advancements for their conditions. With stringent regulations guiding the healthcare landscape in Europe and emphasizing safety and effectiveness standards rigorously upheld across the board; Opicapone emerges as an addition to traditional Levodopa therapy, in addressing Parkinsons disease effectively.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : U.S., Germany, UK, France, Japan are expected to grow at 3.9% to 5.8% CAGR

2

Emerging Markets : Brazil, India, South Africa are expected to grow at 6.9% to 8.3% CAGR

Market Analysis Chart

Opicapone is a remedy for Parkinsons disease with strong factors boosting its popularity in the market scene; its confirmed ability to enhance motor fluctuations in patients has made it a top choice in the healthcare sector worldwide. Thanks, to its simple once daily dosage regimen. It offers a convenient option that appeals especially to the elderly population seeking ease of use. However. Despite these market trends. Opicapone faces some challenges hindering its full market reach.

Recent Developments and Technological Advancement

December 2024

Neurocrine Biosciences revealed an advancement in Opicapone investigation by highlighting its possible advantages, for Neurodegenerative conditions.

October 2024

The Opicapone market experienced increased competition when Sun Pharmaceutical Industries entered the scenario as a player looking to take advantage of theindustry'sgrowth patterns.

July 2024

The original creators of Opicapone at Bial Portela & Co. Saw a boost in sales thanks, to marketing approaches that centered on engaging customers through digital channels.

Opicapone has become a player in the realm of Parkinsons disease treatment and has been showing notable progress in the market The ongoing research advancements on this COMT inhibitor medication have laid a solid foundation for its potential use in addressing fluctuations seen in Parkinsons disease patients Its worth acknowledging the growing emphasis on personalized healthcare, within the pharmaceutical sector.

Impact of Industry Transitions on the Opicapone Market

As a core segment of the Pharmaceutical industry, the Opicapone market develops in line with broader industry shifts. Over recent years, transitions such as The Advent of Personalized Medicine and Emphasizing RealWorld Evidence have redefined priorities across the Pharmaceutical sector, influencing how the Opicapone market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

The Advent of Personalized Medicine:

The rise of medicine has made it common to customize treatments for each patient nowadays. Especially noticeable in the pharmaceutical sector with medications such as Opicapone being a prime example of this trend shift, in Parkinsons disease treatment plans. Opicapone is a COMT inhibitor utilized to treat Parkinsons disease. Is now being personalized to suit individual patient needs better. Resulting in enhanced treatment results and decreased side effects. This marks the beginning of an era centered around patient care improvement which enhances patient contentment and overall treatment effectiveness.

2

Emphasizing RealWorld Evidence:

Real world evidence plays a role in pharmaceutical research and development nowadays with substances like Opicapone being extensively studied in real world scenarios to assess their efficacy and safety levels accurately based on actual patient data and experiences rather than solely relying on randomized clinical trials This shift has notably advanced the market, for Opicapone by enhancing drug development approaches and fostering trust in evidence based patient treatment strategies.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Opicapone market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Rising Prevalence of Parkinsons Disease

The significant rise in Parkinsons Disease cases is also driving the growth of the Opicapone market significantly. Opicapone has also been approved as a COMT inhibitor for treating Parkinsons disease. Holds great promise in serving the growing number of patients with this condition. The growing elderly population is also one of the risk factors for Parkinsons disease and emphasizes the need for continued demand for Opicapone, as an essential treatment option.
Advancements in drug delivery technology have also enhanced the accessibility and effectiveness of Opicapone for patients by introducing extended release formulations and improved oral dosages methods that result in patient outcomes and also experiences. The increasing demand for Opicapone is also driven by these innovations. Continued developments, in this field may also elevate Opicapones market standing and importance even more.

Restraint: Regulatory Challenges

Tough regulations and approval procedures can pose challenges in the Opicapone market space despite its proven effectiveness in treating Parkinsons disease The stringent pharmaceutical regulatory environment mandates rounds of clinical trials which are both time consuming and costly This could potentially hamper the growth and interest in Opicapone hurdles arise with modifications in composition or usage that limit avenues, for growth and creativity.

Challenge: Competition from Alternative Treatments

The market dynamics of Opicapone are significantly influenced by the existence of treatment options for Parkinsons disease such as Levodopa and physical therapies which create strong competition for it. Along with the research into new therapies intensifying this competition further this impacts Opicapones market share. Despite Opicapones established efficacy in symptom management and disease progression control the presence of treatments poses a significant challenge, to its market demand.

Supply Chain Landscape

Raw Material Sourcing

Pfizer Inc.

Merck KGaA

Intermediate Manufacturing

BIAL

Neurocrine Biosciences

Formulation & Processing
GW Pharmaceuticals / AbbVie
Packaging & Distribution
Allergan / Novartis
Raw Material Sourcing

Pfizer Inc.

Merck KGaA

Intermediate Manufacturing

BIAL

Neurocrine Biosciences

Formulation & Processing

GW Pharmaceuticals

AbbVie

Packaging & Distribution

Allergan

Novartis

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Parkinson's Disease Management
Pharmaceuticals
BIAL
Optimising treatment regimen by combining Opicapone with levodopa and carbidopa
Neurology Research
Healthcare and Research
Neurocrine Biosciences
Investing in the exploration of Opicapone's broader impact on neurological disorders
Drug Development
Biotechnology
Teva Pharmaceuticals
Development of more potent, less toxic formulations with Opicapone for advanced clinical treatment options

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Opicapone market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Opicapone in Drug Combination Therapy and Neurodegenerative Disease Management and Parkinson's Disease Treatment

Drug Combination Therapy and Neurodegenerative Disease Management

In the realm of combining medications for treatment purposes Opicapone holds a position. When paired with medications such as levodopa and carbidopa it enhances the availability of levodopa in the brain thereby improving the overall effectiveness of the treatment. The key advantage of this application lies in the efficacy resulting from the combination of these drugs, which ultimately leads to improved management of the disease. Johnson & Johnson a player in this field showcases remarkable performance and market presence attributed to its holistic approach, towards innovative treatment techniques.

Opicapone is known for its effectiveness in treating neurodegenerative disorders due, to its strong ability to inhibit COMTs . It helps regulate motor symptoms linked to these illnesses by boosting dopamine levels in the brain.

Parkinson's Disease Treatment

Opicapone is mostly used to help with Parkinsons Disease – a neurological condition to deal with in daily life for many individuals affected by it. Acting as a COMT inhibitor; Opicapone aids in making levadopa therapy more effective in managing the symptoms of this disease that are motor related. One of the advantages of using this treatment is the noticeable improvement seen in motor symptoms and an overall increase in the quality of life for patients dealing with Parkinsons Disease. Standing out as a leader in this field is BIAL; recognized for their strong focus on innovation within the pharmaceutical industry and their successful positioning within the market, through their product Ongentys.

Opicapone vs. Substitutes:
Performance and Positioning Analysis

Opicapone is a highly effective, once-daily treatment for Parkinsons disease, offering significant advantages in efficacy and convenience over traditional alternatives like Entacapone. As a key player in the niche market, Opicapone exhibits tremendous potential for growth and expansion. These Alternatives specially Pramipexole has experienced a rapid growth as detailed in our latest report.

Opicapone
  • Entacapone /
  • Tolcapone /
  • Pramipexole
    Effective in management of Parkinsons disease symptoms, Extended duration of action
    High cost, Potential side effects including dyskinesia and hallucinations
    Superior efficacy, Minimal side effects
    High cost, Limited availability

Opicapone vs. Substitutes:
Performance and Positioning Analysis

Opicapone

  • Effective in management of Parkinsons disease symptoms, Extended duration of action
  • High cost, Potential side effects including dyskinesia and hallucinations

Entacapone / Tolcapone / Pramipexole

  • Superior efficacy, Minimal side effects
  • High cost, Limited availability

Opicapone is a highly effective, once-daily treatment for Parkinsons disease, offering significant advantages in efficacy and convenience over traditional alternatives like Entacapone. As a key player in the niche market, Opicapone exhibits tremendous potential for growth and expansion. These Alternatives specially Pramipexole has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Opicapone market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Opicapone across Parkinson's Disease Management and Adjunct Therapy with Levodopa Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as BIAL-Portela & CA S.A., Allergan, and Teva Pharmaceuticals Industries Ltd. by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Sourcing, Intermediate Manufacturing, and Formulation & Processing. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Opicapone segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Sourcing (Pfizer Inc., Merck KGaA), Intermediate Manufacturing (BIAL, Neurocrine Biosciences), and Formulation & Processing. Our parallel substitute analysis examines Entacapone, Tolcapone, and Pramipexole, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as BIAL-Portela & CA S.A., Allergan, and Teva Pharmaceuticals Industries Ltd., analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Opicapone market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Opicapone Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 757 million
Revenue Forecast in 2034USD 1.28 billion
Growth RateCAGR of 6.0% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 2024714 million
Growth OpportunityUSD 565 million
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD million and Industry Statistics
Market Size 2024714 million USD
Market Size 2027850 million USD
Market Size 2029955 million USD
Market Size 20301.01 billion USD
Market Size 20341.28 billion USD
Market Size 20351.36 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredDrug Formulation, Distribution Channel, Therapeutic Application, Patient Demographics
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledBIAL-Portela & CA S.A., Allergan, Teva Pharmaceuticals Industries Ltd., Takeda Pharmaceutical Company Limited, Novartis International AG, Lundbeck LLC, GlaxoSmithKline Plc, UCB Group, Synthon Holdings B.V., Cipla Inc., Sun Pharmaceutical Industries Ltd. and ApoPharma USA Inc.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Opicapone Market Size, Opportunities & Strategic Insights, by Drug Formulation

4.1Capsule
4.2Tablet
Chapter 5

Opicapone Market Size, Opportunities & Strategic Insights, by Distribution Channel

5.1Hospital Pharmacies
5.2Retail Pharmacies
5.3Online Pharmacies
Chapter 6

Opicapone Market Size, Opportunities & Strategic Insights, by Therapeutic Application

6.1Parkinson's Disease Management
6.2Adjunct Therapy with Levodopa
Chapter 7

Opicapone Market Size, Opportunities & Strategic Insights, by Patient Demographics

7.1Geriatric Patients
7.2Adult Patients
Chapter 8

Opicapone Market, by Region

8.1North America Opicapone Market Size, Opportunities, Key Trends & Strategic Insights
8.1.1U.S.
8.1.2Canada
8.2Europe Opicapone Market Size, Opportunities, Key Trends & Strategic Insights
8.2.1Germany
8.2.2France
8.2.3UK
8.2.4Italy
8.2.5The Netherlands
8.2.6Rest of EU
8.3Asia Pacific Opicapone Market Size, Opportunities, Key Trends & Strategic Insights
8.3.1China
8.3.2Japan
8.3.3South Korea
8.3.4India
8.3.5Australia
8.3.6Thailand
8.3.7Rest of APAC
8.4Middle East & Africa Opicapone Market Size, Opportunities, Key Trends & Strategic Insights
8.4.1Saudi Arabia
8.4.2United Arab Emirates
8.4.3South Africa
8.4.4Rest of MEA
8.5Latin America Opicapone Market Size, Opportunities, Key Trends & Strategic Insights
8.5.1Brazil
8.5.2Mexico
8.5.3Rest of LA
8.6CIS Opicapone Market Size, Opportunities, Key Trends & Strategic Insights
8.6.1Russia
8.6.2Rest of CIS
Chapter 9

Competitive Landscape

9.1Competitive Dashboard & Market Share Analysis
9.2Company Profiles (Overview, Financials, Developments, SWOT)
9.2.1BIAL-Portela & CA S.A.
9.2.2Allergan
9.2.3Teva Pharmaceuticals Industries Ltd.
9.2.4Takeda Pharmaceutical Company Limited
9.2.5Novartis International AG
9.2.6Lundbeck LLC
9.2.7GlaxoSmithKline Plc
9.2.8UCB Group
9.2.9Synthon Holdings B.V.
9.2.10Cipla Inc.
9.2.11Sun Pharmaceutical Industries Ltd.
9.2.12ApoPharma USA Inc.